文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

兰瑞肽预防术后胰瘘(S2408):多中心随机对照试验方案

Lanreotide for the prevention of postoperative pancreatic fistula (S2408): study protocol for a multicenter randomized controlled trial.
PubMed 文献 · Trials · 2026-08-03

S2408 是多中心 III 期随机对照试验,比较术前单次兰瑞肽 120 mg 皮下注射与生理盐水安慰剂在远端胰腺切除患者中术后 60 天内胰瘘发生率,计划入组 274 例,由美国国家癌症研究所癌症预防部资助。

要点

  • 术前单次兰瑞肽 120 mg 皮下注射用于远端胰腺切除患者预防术后胰瘘。
  • 主要终点为术后 60 天内胰瘘发生率,计划入组 274 例。
  • 次要终点包括生化漏、胃排空延迟、术后胰切除出血、住院时长及癌症特异性生活质量变化。

核心结论

  • S2408 旨在验证术前单次兰瑞肽较安慰剂可降低远端胰腺切除患者术后胰瘘发生率的假设。

研究设计与样本

  • S2408 为多中心 III 期随机对照试验,由美国国家癌症研究所癌症预防部资助。
  • 计划在北美学术与社区医院入组 274 例疑似或活检证实胰腺恶性肿瘤、拟行远端胰腺切除的参与者。
  • 参与者随机接受术前单次兰瑞肽 120 mg 皮下注射或生理盐水安慰剂。

主要发现

  • 术后胰瘘估计影响 25-30% 的远端胰腺切除患者。
  • 单项 II 期单臂试验中,术前单次兰瑞肽与胰十二指肠切除和远端胰腺切除患者低胰瘘率 11% 和 3% 相关。

关键数值与推荐

  • 主要目标为比较两组术后 60 天内胰瘘发生率。
  • 次要目标包括比较术后 60 天内生化漏、胃排空延迟、术后胰切除出血发生率、术后住院时长及癌症特异性生活质量自基线变化。
  • 血液、引流液和组织标本将储存用于未来相关性研究。

临床怎么用

  • 若试验证实有效,术前单次兰瑞肽可能成为远端胰腺切除术后胰瘘的预防选择。

局限性

  • 现有兰瑞肽证据来自单项 II 期单臂试验,样本量有限且缺乏对照。
  • 既往帕瑞肽随机试验因单中心设计、给药方案不便及高剂量限制性副作用受到批评。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative pancreatic fistula (POPF) remains the defining complication of pancreatectomy, leading to significant morbidity, mortality, and increased healthcare costs. Multiple studied interventions have failed to meaningfully reduce the incidence of POPF, which is estimated to affect 25-30% of distal pancreatectomy patients. Since the early 1990s, studies have explored the role of perioperative somatostatin analogs (SSAs) for POPF prophylaxis, including octreotide. A randomized trial of perioperative pasireotide reported a reduced incidence of POPF, but faced criticism due to its single-center design, inconvenient dosing regimen, and pasireotide's high rate of dose-limiting side effects. Lanreotide is a more recently developed SSA with a simpler dosing regimen due to its depot formulation and a favorable side-effects profile that has been proposed for POPF prophylaxis. In a single-arm phase II trial, a single dose of preoperative lanreotide was associated with low POPF rates of 11% and 3% in patients undergoing pancreaticoduodenectomy (PD) and distal pancreatectomy (DP), respectively. METHODS: S2408 is a multicenter, phase III randomized controlled trial sponsored by the National Cancer Institute Division of Cancer Prevention comparing the incidence of POPF in participants receiving a single dose of preoperative lanreotide (120 mg subcutaneous) versus saline placebo immediately prior to DP for suspected or biopsy-proven pancreatic malignancy. Planned enrollment of 274 participants will take place at academic and community hospitals in North America. The primary objective is to compare the incidence of POPF within 60 days after surgery between treatment groups. Secondary objectives include comparing the incidences of other postoperative sequelae (biochemical leak, delayed gastric emptying, post-pancreatectomy hemorrhage) within 60 days of surgery, postoperative length of hospital stay, and changes from baseline in cancer-specific quality of life between treatment groups. Blood, drain fluid, and tissue specimens will be banked for future correlative studies. DISCUSSION: S2408 is a multicenter clinical trial designed to evaluate the hypothesis that a single dose of preoperative lanreotide will reduce the incidence of POPF in patients undergoing DP compared to placebo. TRIAL REGISTRATION: ClinicalTrials.gov NCT06807437. Registered on February 2, 2025. Trial opened for accrual February 14, 2025. URL: https://clinicaltrials.gov/study/NCT06807437 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Intara AS, Guthrie KA, Chauhan SSB, et al. Lanreotide for the prevention of postoperative pancreatic fistula (S2408): study protocol for a multicenter randomized controlled trial. Trials. 2026. PMID: 42958416. doi:10.1186/s13063-026-09933-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。